Roche Enspryng: Oct 15 TED PDUFA vs Tepezza

Roche’s ADR (RHHBY) closed Tuesday at $58.47, and the parent company carries a market cap near $354 billion. On October 15, 2026, the FDA decides whether Enspryng, Roche’s satralizumab, becomes the first at-home subcutaneous disease-modifying therapy for thyroid eye disease. The framing everyone will reach for is wrong. This is not a Roche growth story. It is an Amgen franchise-risk story.

Thyroid eye disease, or TED, affects roughly 155 out of every 100,000 people, which works out to around half a million Americans with some form of the condition. Most cases are mild and never reach a biologic, but the moderate-to-severe active population is the commercially valuable slice. Since 2020 that slice has been a de facto monopoly. Tepezza (teprotumumab), the IGF-1R antibody Amgen acquired with Horizon Therapeutics in 2023, is the only approved disease-modifying therapy, and it is given by intravenous infusion. Tepezza did $1.9 billion in 2025 sales, up just 3% year over year. The fourth quarter was worse: $457 million, down 1% year over year, held up only by 11% volume growth that was partially offset by 13% lower inventory. That slowing trajectory is the tell: the TED market has matured, and Tepezza’s growth is now single digits.

Satralizumab attacks a different target. It is an anti-IL-6 receptor antibody, already approved as Enspryng for neuromyelitis optica spectrum disorder (NMOSD) in roughly 90 countries with a safety record built across more than 10,000 patients. It uses a recycling antibody technology that binds the IL-6 receptor repeatedly for sustained suppression, and it is given by a monthly subcutaneous injection at home after an initial loading period. The TED filing is a label expansion, an sBLA, which makes it lower binary risk than a first approval. The mechanism matters: IL-6 drives the orbital inflammation behind TED, a different biology from Tepezza’s IGF-1R pathway and from the FcRn approach that has now failed twice in this disease.

The Phase 3 data are good but not clean. SatraGO-1 (NCT05987423) and SatraGO-2 (NCT06106828) were identically designed trials enrolling 258 patients across 19 countries, randomized 1:1 to Enspryng or placebo. The trials enrolled both active moderate-to-severe TED and chronic inactive TED, though the primary analysis focused on the active population. The primary endpoint was the share of patients achieving at least a 2 mm reduction in proptosis, or eye bulging, at week 24. In SatraGO-2, 53% of Enspryng patients hit that bar versus 23% on placebo, a statistically significant result. In SatraGO-1, 49% versus 31%, a directional miss that did not reach statistical significance (Roche press release).

That split verdict is the crux of the regulatory risk. Roche is filing on one clearly positive trial and one trial that trended the right way but missed. On secondary endpoints the picture is more consistent: diplopia, or double vision, improved in 44% to 61% of patients, and clinical activity score improved in 78% to 90%. But the FDA does not approve on secondaries alone when one of two registrational primary endpoints missed.

Part of the split is a placebo-rate story, and that cuts both ways. SatraGO-1’s placebo arm hit 31% proptosis response versus 23% in SatraGO-2, which is the main reason the same drug produced one significant and one non-significant result. High placebo response is a known TED problem, because patients in trials receive supportive care that improves outcomes on its own. Regeneron and Roche will argue the drug was consistent and the placebo arm was noisy. A regulator cannot simply wave away a missed primary endpoint by blaming the placebo arm, but an advisory committee will at least hear the argument.

The market math reframes the trade. Tepezza’s $1.9 billion sits inside Amgen, a $240 billion company, where TED is a meaningful growth asset that Amgen bought and has defended. Amgen is not sitting still: it announced positive Phase 3 topline results for a subcutaneous Tepezza in April 2026. So the very convenience edge Enspryng is built on is being answered by the incumbent before Enspryng even reaches market. That is the real risk to the bull case.

For Roche, the numbers are almost insultingly small. A $354 billion company adding a TED indication to a drug already approved for NMOSD is a line item, not a thesis. Roche already owns the leading retinal franchise in Vabysmo and Susvimo, so an eye indication fits a division that is already built, but it is still a line item. Even if Enspryng took a third of the TED market, that is a few hundred million dollars against Roche’s roughly $75 billion in annual revenue. Roche’s stock will not move on October 15 regardless of the outcome.

One genuine differentiator survives the split data. Tepezza is labeled only for active TED, the inflammatory phase. SatraGO also enrolled patients with chronic inactive TED, the fibrotic phase where bulging and double vision persist after the inflammation has burned out. If the FDA grants Enspryng a label that includes chronic inactive TED, it opens a patient population Tepezza does not serve, and the market grows rather than just being divided. The dosing contrast is real too: a monthly at-home injection against Tepezza’s course of roughly eight intravenous infusions spread over about six months. Convenience is not a trivial edge in a disease where the treatment itself is a burden.

The small-cap angle everyone asks about does not exist. Immunovant’s batoclimab, an FcRn inhibitor, failed both of its Phase 3 TED trials on the same 2 mm proptosis endpoint, and argenx quietly discontinued Vyvgart in TED after its own trials looked set to miss (the FcRn class story is here). The FcRn mechanism, so dominant in myasthenia gravis, does not transfer to the eye. The biology is the reason: in gMG, FcRn blockade works by lowering the circulating IgG autoantibodies that sit at the neuromuscular junction. In TED, the pathogenic driver is orbital fibroblast proliferation and inflammation that FcRn blockade does not meaningfully touch. That leaves no investable small-cap pure play in TED. The pure plays are two mega-caps, and neither is a trade here.

So what does October 15 actually change? For Amgen, a Tepezza challenger is real but the financial hit is spread across a $240 billion base, and Amgen’s subcutaneous Tepezza blunts the differentiation. For Roche, the approval is immaterial. The verdict: this is a franchise story for two mega-caps with no tradeable catalyst. Watch it for the read-through, but do not build a position around it. If you must express a view, the more exposed company is Amgen, and even there, wait for the subcutaneous Tepezza launch data before acting.

There is a broader lesson here that matters more than the trade. A franchise-extension sBLA on a drug already approved in another indication is a fundamentally different bet from a first approval. The binary risk is lower, the stock impact is lower, and the real story is almost always competitive share, not clinical validation. That is why the FcRn failures in TED are more instructive than Enspryng’s own data: three different mechanisms have now attacked this disease, and the only two winners so far are the IGF-1R incumbent and an IL-6 challenger with one clean win and one near miss.

The risks to name: the SatraGO-1 primary endpoint miss is the biggest one, and an FDA advisory committee could read the split data as insufficient. The IL-6 mechanism carries an infection risk profile that, while established in NMOSD, is being extended to a less severe disease where patients weigh side effects against a quality-of-life drug. And Amgen’s subcutaneous Tepezza could nullify Enspryng’s only structural advantage before Roche commercializes it. This is a fight between two pharma giants over a market that is already slowing, and that is rarely where breakout returns come from. For the next real catalyst in the retina and eye space, track the retina PDUFA calendar instead.